Preclinical and in vitro assessment of the potential of D0870, an antifungal agent, for producing clinical drug interactions

Xenobiotica

Volumn 29, Issue 4, 1999, Pages 395-408

  McKillop, D ^a   Back, D J ^b   McCormick, A D ^a   Evans, J A ^a   Tjia, J ^b  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DIFLUOROPHENYL) 1 [3 [2 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL]VINYL] 1,2,4 TRIAZOL 1 YL] 3 (1,2,4 TRIAZOL 1 YL) 2 PROPANOL; ALDRIN EPOXIDASE; ANTIFUNGAL AGENT; CARBON 14; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DEBRISOQUINE 4 HYDROXYLASE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; OXYGENASE; PENTOBARBITAL; PHENACETIN O DEETHYLASE; QUINIDINE; TOLBUTAMIDE HYDROXYLASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER CELL; LIVER MICROSOME; MALE; METABOLITE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; SLEEP TIME;

ANIMALS; ANTIFUNGAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; INHIBITORY CONCENTRATION 50; KINETICS; MALE; MICROSOMES, LIVER; MODELS, CHEMICAL; PENTOBARBITAL; RATS; TIME FACTORS; TRIAZOLES;

ANIMALIA;

EID: 0032910986     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982599238579     Document Type: Article

References (58)

1. ABEL, S. M., MAGGS, J. L., BACK, D. J. and PARK, B. K., 1992, Cortisol metabolism by human liver in vitro - I. Metabolite identification and inter-individual variability. Journal of Steroid Biochemistry and Molecular Biology, 43, 713-719.
2. AHONEN, J., OLKKOLA, K. T. and NEUVONEN, P.J., 1995, Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. British Journal of Clinical Pharmacology, 40, 270-272.
3. ANDERSSON, T., MINERS, J. O., VERONESE, M. E. and BIRKETT, D. J., 1994, Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. British Journal of Clinical Pharmacology, 37, 597-604.
4. BACIEWICZ, A. M. and BACIEWICZ, F. A., 1993, Ketoconazole and fluconazole drug interactions. Archives of Internal Medicine, 153, 1970-1976.
5. BACK, D. J. and TJIA, J. F., 1991, Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. British Journal of Clinical Pharmacology, 32, 624-626.
6. BADER, A., KNOP, E., BÖKER, K. H. W., CROME, O., FRÜHAUF, N., GONSCHIOR, A. K., CHRISTIANS, U., ESSELMANN, H., PICHLMAYR, R. and SEWING, K. F., 1996, Tacrolimus (FK 506) biotransformation in primary rat hepatocytes depends on extracellular matrix geometry. Naunyn-Schmiedeberg's Archive of Pharmacology, 353, 461-473.
7. BADER, A., ZECH, K., CROME, O., CHRISTIANS, U., RINGE, B., PICHLMAYR, R. and SEWING, K.-F. R., 1994, Use of organotypical cultures of primary hepatocytes to analyse drug biotransformation in man and animals. Xenobiotica, 24, 623-633.
8. BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARKE, S. E. and CHENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica, 25, 261-270.
9. BIRKETT, D. J., MACKENZIE, P. I., VERONESE, M. E. and MINERS, J. O., 1993, In vitro approaches can predict human drug metabolism. Trends in Pharmaceutical Science, 14, 292-294.
10. BLACK, D. J., KUNZE, K. L., WIENKERS, L. C., GIDAL, B. E., SEATON, T. L., MCDONNELL, N. D., EVANS, J. S., BAUWENS, J. E. and TRAGER, W. F., 1996, Warfarin-Fluconazole II. A metabolically based drug interaction: In vivo studies. Drug Metabolism and Disposition, 24, 422-428.
11. BLUM, R. A., WILTON, J. H., HILLIGOSS, D. H., GARDNER, M. J., HENRY, E. B., HARRISON, N. J. and SCHENTAG, J. J., 1991, Effect of fluconazole on the disposition of phenytoin. Clinical Pharmacology and Therapeutics, 49, 420-425.
12. COMO, J. A. and DISMUKES, W. E., 1994, Oral azole drugs as systemic antifungal therapy. New England Journal of Medicine, 330, 263-272.
13. 1 activity. Clinical Pharmacology and Therapeutics, 45, 34-40.
14. DE WIT, S., O'DOHERTY, E., EDWARDS, J., YATES, R., SMITH, R. P. and CLUMECK, A. N., 1998, Pharmacokinetics of two multiple-dosing regimens of D0870 in human immunodeficiency virus-positive patients: a Phase I study. Antimicrobial Agents and Chemotherapy, 42, 903-906.
15. GUENGERICH, P. F., ENOCH, M. D. and BLAIR, I. D., 1986, Oxidation of quinidine by human liver cytochrome P450. Molecular Pharmacology, 30, 287-294.
16. HONIG, P. K., WORTHAM, D. C., ZAMANI, K., CONNER, D. P., MULLIN, J. C. and CANTILENA, L. R., 1993, Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. Journal of the American Medical Association, 269, 1513-1518.
17. HOSTETLER, K. A., WRIGHTON, S. A., MOLOWA, D. T., THOMAS, P. E., LEVIN, W. and GUZELIAN, P. S., 1989, Coinduction of multiple cytochrome P450 proteins and their mRNAs in rats treated with imidazole antimycotic agents. Molecular Pharmacology, 35, 279-285.
18. HOUSTON, J. B., HUMPHREY, M. J., MATTHEW, D. E. and TARBIT, M. H., 1988, Comparison of two azole antifungal drugs, ketoconazole and fluconazole, as modifiers of rat hepatic monooxygenase activity. Biochemical Pharmacology, 37, 401-408.
19. KNOP, E., BADER, A., BÖKER, K., PICHLMAYR, R. and SEWING, K. F., 1995, Ultrastructural and functional differentiation of hepatocytes under long-term culture conditions. The Anatomical Record, 242, 337-349.
20. KRAMER, M. R., MARSHALL, S. E., DENNING, D. W., KEOGH, A. M., TUCKER, R. M., GALGIANI, J. N., STEVENS, D. A. and THEODORE, J., 1990, Cyclosporine and itraconazole interaction in heart and lung-transplant recipients. Annals of Internal Medicine, 113, 327-329.
21. KRISHNAIAH, Y. S. R., SATYANARAYANA, S. and VISWESWARAM., D., 1994, Interaction between tolbutamide and ketoconazole in healthy subjects. British Journal of Clinical Pharmacology, 37, 205-207.
22. KUNZE, K. L., WIENKERS, L. C., THUMMEL, and TRAGER, W. F., 1996, Warfarin-Fluconazole I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: In vitro studies. Drug Metabolism and Disposition, 24, 414-421.
23. LAVRIJSEN, K., VAN HOUDT, J., THIJS, D., MEULDERMANS, W. and HEYKANTS, J., 1986, Induction potential of antifungals containing an imidazole or triazole moiety. Biochemical Pharmacology, 35, 1867-1878.
24. LAVRIJSEN, K., VAN HOUDT, J., THIJS, D., MEULDERMANS, W. and HEYKANTS, J., 1987, Interaction of miconazole, ketoconazole and itraconazole with rat-liver microsomes. Xenobiotica, 17, 45-57.
25. LAVRIJSEN, K. L. M., VAN HOUDT, J. M. G., VAN DYCK, D. M. J., MEULDERMANS, W. E. G. and HEYKANTS, J. J. P., 1990, Induction potential of fluconazole toward drug-metabolising enzymes in rats. Antimicrobial Agents and Chemotherapy, 34, 402-408.
26. LAZAR, J. D. and WILNER, K. D., 1990, Drug-interactions with fluconazole. Reviews of Infectious Diseases, 12, S327-333.
27. MCKILLOP, D., 1985, Effects of phenobarbitone and β-naphthoflavone on hepatic microsomal drug metabolising enzymes of the male beagle dog. Biochemical Pharmacology, 34, 3137-3142.
28. MEREDITH, C. G., MALDOADO, A. L. AND SPEEG, K. V. Jr, 1985, The effect of ketoconazole on hepatic oxidative drug metabolism in the rat in vivo and in vitro. Drug Metabolism and Disposition, 13, 156-162.
29. MEIER, U. T., KRONBACH, T. AND MEYER, U. A., 1985, Assay of mephenytoin metabolism in human microsomes by high performance liquid chromatography. Analytical Biochemistry, 151, 286-291.
30. MINERS, J. O., SMITH, K. J., ROBSON, R. A., MCMANUS, M. E., VERONESE, M. E. and BIRKETT, D. J., 1988, Tolbutamide hydroxylation by human liver microsomes. Biochemical Pharmacology, 37, 1137-1144.
31. NAVJAR, L. K., CORREA, A., JAMES, P., LUTHER, M. F. and GRAYBILL, J. R., 1996, D0870 treatment of murine candidiasis caused by fluconazole resistant isolates of Candida albicans. Journal of Antimicrobial Chemotherapy, 38, 671-677.
32. NEWMAN, S. L. and GUZELIAN, P. S., 1983, Identification of the cyanopregnenolone-inducible form of hepatic cytochrome P450 as a catalyst of aldrin epoxidation. Biochemical Pharmacology, 32, 1529-1531.
33. NEWTON, D. J., WANG, R. W. and LU, A. Y. H., 1995, Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154-158.
34. OLKKOLA, K. T., BACKMAN, J. T. and NEUVONEN, P. J., 1994, Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clinical Pharmacology and Therapeutics, 55, 481-485.
35. PARKINSON, A., CLEMENT, R. P., CASCIANO, C. N. and CAYEN, M. N., 1992, Evaluation of loratidine as an inducer of liver microsomal cytochrome P450 in rats and mice. Biochemical Pharmacology, 43, 2169-2180.
36. PECK, J. J., TEMPLE, R. and COLLINS, J. M., 1993, Understanding consequences of concurrent therapies. Journal of the American Medical Association, 269, 1550-1552.
37. POHJOLA-SINTONEN, S., VIITASALO, M., TOIVONEN, L. and NEUVONEN, P., 1993, Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. European Journal of Clinical Pharmacology, 45, 191-193.
38. PURBA, H. S., MAGGS, J. L., ORME, M. L. E., BACK, D. J. and PARK, B. K., 1987, The metabolism of 17α-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites. British Journal of Clinical Pharmacology, 23, 447-453.
39. RAMZAN, I. and CHAN, M., 1993, Influence of fluconazole on antipyrine kinetics in rats. European Journal of Drug Metabolism and Pharmacokinetics, 18, 273-276.
40. REESE, J. A. and BYARD, J. L., 1981, Isolation and culture of adult rat hepatocytes from liver biopsies. In vitro, 17, 935-941.
41. RING, B. J., BINKLEY, S. N., VANDENBRANDEN, M. and WRIGHTON, S. A., 1996, In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A British Journal of Clinical Pharmacology, 41, 181-186.
42. RITTER, J. K. and FRANKLIN, M. R., 1987, High magnitude hepatic cytochrome P450 induction by an N-substituted imidazole antimycotic, clotrimazole. Biochemical Pharmacology, 36, 2783-2787.
43. RODRIGUES, A. D., 1994, Use of in vitro human metabolism studies in drug development: An industrial perspective. Biochemical Pharmacology, 48, 2147-2156.
44. RODRIGUES, A. D., LEWIS, D. F. V., IOANNIDES, C. and PARKE, D. V., 1987, Spectral and kinetic studies of the interaction of imidazole anti-fungal agents with microsomal cytochromes P450. Xenobiotica, 17, 1315-1327.
45. SHEETS, J. J. and MASON, J. I., 1984, Ketoconazole: A potent inhibitor of cytochrome P450-dependent drug metabolism in rat liver. Drug Metabolism and Disposition, 12, 603-606.
46. TASSANEEYAKUL, W., VERONESE, M. E., BIRKETT, D. J., DOECKE, C. J., MCMANUS, M. E., SANSOM, L. N. and MINERS, J. O., 1992, Co-regulation of phenytoin and tolbutamide metabolism in humans. British Journal of Clinical Pharmacology, 34, 494-498.
47. THOMSON, R. G., RAWLINS, M. D., JAMES, O. F. W., WOOD, P. and WILLIAMS, F. M., 1988, The acute and subchronic effects of ketoconazole on hepatic microsomal monooxygenases in the rat. Biochemical Pharmacology, 37, 3975-3980.
48. TJIA, J. F., COLBERT, J. and BACK, D. J., 1996, Theophylline metabolism in human liver microsomes: Inhibition studies. Journal of Pharmacology and Experimental Therapeutics, 276, 912-917.
49. TOUCHETTE, M. A., CHANDRASEKAR, P. H., MILAD, M. A. and EDWARDS, D. J., 1992, Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man. British Journal of Clinical Pharmacology, 34, 75-78.
50. UENG, Y.-F., KUWABARA, T., CHUN, Y.-J. and GUENGERICH, F. P., 1997, Cooperativity in oxidations catalysed by cytochrome P450 3A4. Biochemistry, 36, 370-381.
51. VAN DEN BOOSSCHE, H., WILLEMSENS, G., COOLS, W., CORNELLISSEN, F., LAUWERS, W. F. and VAN CUTSEM, J. M., 1980, In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis. Antimicrobial Agents and Chemotherapy, 17, 922-928.
52. VON MOLTKE, L. L., GREENBLATT, D. J., DUAN, S. X., HARMATZ, J. S. and SHADER, R. I., 1994a, In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. Journal of Clinical Pharmacology, 34, 1222-1227.
53. VON MOLTKE, L. L., GREENBLATT, D. J., COTREAU-BIBBO, M. M., HARMATZ, J. S. and SHADER, R. I., 1994b, Inhibitors of alprazolam metabolism in vitro: Effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. British Journal of Clinical Pharmacology, 38, 23-31.
54. VON MOLTKE, L. L., GREENBLATT, D. J., COTREAU-BIBBO, M. M., DUAN, S. X., HARMATZ, J. S. and SHADER, R. I., 1994c, Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vivo. Journal of Pharmacology and Experimental Therapeutics, 268, 1278-1283.
55. WALLE, T., KUMAR, G. N., MCMILLAN, J. M., THORNBURG, K. R. and WALLE, U. K., 1993, Taxol metabolism in rat hepatocytes. Biochemical Pharmacology, 46, 1661-1664.
56. WOLFF, T. and GUENGERICH, F. P., 1988, Rat liver cytochrome P450 sisozymes as catalysts of aldrin epoxidation in reconstituted monooxygenase systems and microsomes. Biochemical Pharmacology, 36, 2581-2588.
57. WRIGHTON, S. A., VANDENBRANDEN, M., STEVENS, J. C., SHIPLEY, L. A., RING, B. J., RETTIE, A. E. and CASHMAN, J. R., 1993, In vitro methods for assessing human hepatic drug metabolism: Their use in drug development. Drug Metabolism Reviews, 25, 453-484.
58. YAMADA, H., TSUDA, T., WATANABE, T., OHASHI, M., MURAKAMI, K. and MOCHIZUKI, H., 1993, In vitro and in vivo antifungal activities of D0870, a new triazole agent. Antimicrobial Agents and Chemotherapy, 37, 2412-2417.